On September 24, 2020 KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, announced it will present new data from its USP1 inhibitor program at the 32nd EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020) taking place virtually October 24-25, 2020 (Press release, KSQ Therapeutics, SEP 24, 2020, View Source [SID1234565587]). Preclinical data on the company’s USP1 inhibitor program will be featured as part of a plenary session highlighting late breaking and best proffered papers, and the company will also present a poster featuring data on its lead USP1 candidate, KSQ-4279.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Plenary Title: "USP1 inhibitors show robust combination activity and a distinct resistance profile from PARP inhibitors."
Session Title: Plenary Session 1: Late Breaking and Best Proffered Papers
Session Date and Time: Saturday, Oct. 24, 2020, 3:05-4:35 PM CEST (9:05-10:35 AM ET)
Poster Title: "Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers."
Poster Number: 184
Session Code: 380
Poster Session Title: New Drugs
Session Date and Time: Saturday, Oct. 24, 2020
"We are pleased to present this exciting data on our industry-leading USP1 inhibitor program and our clinical candidate KSQ-4279 at this year’s ENA meeting," stated Frank Stegmeier, Ph.D., Chief Scientific Officer at KSQ. "We believe USP1 inhibitors may have significant therapeutic benefit across a wide range of cancer types, in particular in combination with well-known standard-of-care therapies such as PARP inhibitors, and we’re excited to present data demonstrating that potential."
The EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium is hosted by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) (Free AACR Whitepaper). The Symposium brings together academics, scientists and pharmaceutical industry representatives from across the globe to learn the latest innovations in drug development, target selection, and the impact of new discoveries in molecular biology. To register for free visit www.eortc.org/ena.